Immuneering Corp
IMRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001790340
No open-market purchases or sales by Immuneering Corp insiders were filed in the last 90 days; 111 institutions reported holding it in 13F filings for Q2 2026, worth $171.6M in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding Immuneering Corp changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 34 | 35 | +1 |
| Shares | 11.7M | 11.8M | +88.4K (+0.8%) |
| Value | $56.9M | $114.9M | +$58.0M (+102.0%) |
New holders (6)
Institutions that held Immuneering Corp at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Bank of Montreal | 96,028 | $1.01M | 0.00% |
| ExodusPoint Capital Management, LP | 86,297 | $838.0K | 0.01% |
| Jane Street Group, LLC | 46,571 | $452.2K | 0.00% |
| Y-Intercept (Hong Kong) Ltd | 11,114 | $107.9K | 0.01% |
| UBS Group AG | 2,713 | $26.3K | 0.00% |
| Cary Street Partner Investment Advisory LLC | 301 | $2.92K | 0.00% |
Sold out (5)
Institutions that held Immuneering Corp at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| T. Rowe Price Investment Management, Inc. | 458,233 | $2.22M |
| Anson Funds Management LP | 32,603 | $158.1K |
| Gsa Capital Partners LLP | 23,371 | $113.0K |
| Qube Research & Technologies Ltd | 19,394 | $94.1K |
| Credit Suisse AG | 58 | $281 |